日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201.

局部用 Jak1/3 抑制剂 ATI-1777 可能在不进行全身用药的情况下使特应性皮炎受益:临床前开发和 2a 期随机对照研究 ATI-1777-AD-201 的结果

Changelian Paul, Xu Canxin, Mnich Steve, Hope Heidi, Kostecki Kourtney, Hirsch Jeff, Loh Chin-Yi, Anderson David, Blinn James, Hockerman Susan, Dick Evan, Smith Walter, Monahan Joseph, Raoof Tooraj, Forman Seth, Burt David, Barnes Brad, Gordon David, Walker Neal, Sudzina John, Tucker Stephen, Jacobsen Jon

Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis

选择性抑制 MK2 通路:来自类风湿性关节炎 IIa 期随机临床试验的数据

Gordon, David; Kivitz, Alan; Singhal, Atul; Burt, David; Bangs, Madison C; Huff, Emma E; Hope, Heidi Rath; Monahan, Joseph B

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study

MK2抑制剂ATI-450在健康受试者中的安全性、耐受性、药代动力学和药效学:一项安慰剂对照、随机I期研究

Gordon, David; Hellriegel, Edward T; Hope, Heidi Rath; Burt, David; Monahan, Joseph B

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma

通过抑制髓母细胞瘤中的 PI3K 通路来干扰对平滑拮抗剂的耐药性

Silvia Buonamici, Juliet Williams, Michael Morrissey, Anlai Wang, Ribo Guo, Anthony Vattay, Kathy Hsiao, Jing Yuan, John Green, Beatriz Ospina, Qunyan Yu, Lance Ostrom, Paul Fordjour, Dustin L Anderson, John E Monahan, Joseph F Kelleher, Stefan Peukert, Shifeng Pan, Xu Wu, Sauveur-Michel Maira, Carl